Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Study of SYD1875 in Advanced Solid Tumors
NCT04202705Phase 1Completed
- Sponsor
- Byondis
- Start
- Feb 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of SYD1875 in solid tumor, sponsored by Byondis. Primary endpoint: Incidence of Dose-Limiting Toxicities at 21 days. Started Feb 2020; status: completed.
02
Drugs
SYD1875
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04202705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202705.